Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of oral azathioprine in ADPKD
2025-524313-86-00Phase 2Withdrawn
- Sponsor
- UZ Leuven
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of azathioprine in autosomal dominant polycystic kidney disease (ADPKD) and Polycystic liver disease (PLD) (2 cohorts), sponsored by UZ Leuven. Primary endpoints: Percentage of treatment discontinuations due to leucopenia, Percentage of treatment discontinuations due to liver function disturbances and 3 more. Planned start Apr 2026; status: withdrawn.
02
Drugs
azathioprine
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)Polycystic liver disease (PLD)
Beyond the preview
Go deeper on 2025-524313-86-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524313-86-00.